PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices

GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices.

Vaccine

Vaccine publishes independent survey showing overwhelming preference for Needle-free technology in large-scale intradermal polio vaccination campaign

The campaign, sponsored by the World Health Organization as part of its polio eradication efforts, vaccinated 500,000 children, aged 4 – 59 months, over a one-week period in early 2019.  Data on acceptability of the PharmaJet Tropis Needle-Free Injection System was collected from 610 vaccinators and 4,898 caregivers.  Of those with prior needle and syringe…

First large-scale polio vaccination campaign using PharmaJet intradermal Needle-free Injector

GOLDEN, Colo. — February 5, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the publication of independent survey results from the first large-scale campaign using its needle-free technology. The paper, entitled Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, was published in Vaccine on January 23, 2020.

Study published in Clinical Cancer Research cites important progress towards new treatments for cancer using PharmaJet Tropis

Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients.

Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

GOLDEN, Colo. — January 8, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors was published in Clinical Cancer Research on November 19, 2019.

PharmaJet Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

GOLDEN, Colo. — December 17, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury and Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies.

Study published in Viruses shows superior response with PharmaJet Tropis over electroporation

Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.

PharmaJet presents latest Research Results at World Vaccine Congress

GOLDEN, Colo. — May 7, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effective-ness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc.

PharmaJet to present latest Research Results at World Vaccine & Immunotherapy Congress

GOLDEN, Colo. — November 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest re-search results at the World Vaccine & Immunotherapy Congress on November 29 at the Loews Coronado Bay Resort in San Diego, California. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

PharmaJet receives Frost & Sullivan Best Practices Award

Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use…